COMMUNIQUÉS West-GlobeNewswire

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
21/07/2026
Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary Fibrosis Company on track to report initial topline data in 2H 2026 AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
European Patent Office Confirms Patent Protection for SOT201, SOTIO's Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
21/07/2026
PRAGUE and BASEL, Switzerland and BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- SOTIO Biotech , a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the Boards of Appeal of the European Patent [...]
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
21/07/2026
Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1 2027 [...]
AssistRx and Medisafe Unite to Power Smarter, More Connected Patient Engagement
21/07/2026
Partnership delivers the real-time status updates and mobile-first engagement today's patients expect from therapy initiation through adherence ORLANDO, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- AssistRx , the advanced [...]
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
21/07/2026
Lonza grants Engitix target-specific license for GlycoConnect ® , HydraSpace ® and SYNtecan E™ linker-payload technologies for ADC development Collaboration enables innovative treatments by combining Lonza’s validated [...]
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions
21/07/2026
New molecular medical device joins Vivex's growing suite of allograft and advanced wound care technologies MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative [...]
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
21/07/2026
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today [...]
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
21/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announced ASC Solutions: an expanded enterprise strategy for ambulatory surgery centers (ASCs) that takes a customer-centric approach to [...]
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
21/07/2026
Aggregate cash dividend of $17.3 million, or approximately $0.40242 per share NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of [...]
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
21/07/2026
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological [...]
Vaxart to Participate in BTIG Biotechnology Conference 2026
21/07/2026
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery [...]
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21/07/2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
21/07/2026
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization [...]
Smile Doctors Appoints Jeff Knudson as CFO to Help Scale Next Phase of Growth
21/07/2026
Former NVA, AMN Healthcare Services and At Home Group executive joins the nation's largest orthodontic support organization (OSO) as it approaches 600 affiliated locations and continues investing in patient care and [...]
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
21/07/2026
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline [...]
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
21/07/2026
A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against [...]
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
21/07/2026
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties [...]
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
21/07/2026
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a [...]
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
21/07/2026
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed a regional agreement [...]

Pages